Table 1.
Clinical, Genetic and Sociodemographic Characteristics of the Study Patients by Kidney Transplant Status
| Characteristic | Patients without Kidney Transplants (n=1630) |
Kidney Transplant Recipients (n=65) |
P Value | |
|---|---|---|---|---|
| Age (years) | 61.6 ± 15.8 | 53.8 ± 13.9 | < 0.001 | |
| Height (inches) | 67.6 ± 4.1 | 67.5 ± 4.7 | 0.92 | |
| Weight (pounds) | 196.9 ± 50.9 | 192.2 ± 46.7 | 0.47 | |
| Body mass index (kg/m2) | 30.3 ± 7.7 | 29.5 ± 6.4 | 0.36 | |
| Warfarin dose (mg/day) | 5.6 ± 5.5 | 4.7 ± 4.2 | 0.0005 | |
| eGFR (ml/min/1.73 m2) | 69.6 ± 29.4 | 44.3 ± 33.4 | < 0.001 | |
|
| ||||
| Female | 804 (49.3%) | 25 (38.5%) | 0.086 | |
| African-American | 711 (43.6%) | 32 (49.2%) | 0.37 | |
| Current smoker | 200 (12.3%) | 5 (7.7%) | 0.27 | |
| Indication for warfarin therapya | ||||
| Venous thromboembolism | 690 (43.1%) | 41 (63.1%) | 0.004 | |
| Atrial fibrillation | 673 (42.1%) | 18 (27.7%) | ||
| Stroke, transient ischemic attack, or other | 237 (14.6%) | 6 (9.2%) | ||
| Comorbid conditions | ||||
| Hypertension | 1002 (67.0%) | 52 (80.0%) | 0.029 | |
| Hyperlipidemia | 727 (48.6%) | 39 (60.0%) | 0.073 | |
| Diabetes mellitus | 472 (31.6%) | 28 (43.08%) | 0.052 | |
| Congestive heart failure | 343 (22.9%) | 14 (21.5%) | 0.79 | |
| Kidney function | ||||
| eGFR ≥ 60 ml/min/1.73 m2 | 962 (64.2%) | 19 (29.7%) | < 0.001 | |
| eGFR ≥ 30–59 ml/min/1.73 m2 | 427 (28.5%) | 19 (29.7%) | ||
| eGFR < 30 ml/min/1.73 m2 | 109 (7.3%) | 26 (40.6%) | ||
| Concurrent medications | ||||
| Statinsb | 819 (54.7%) | 52 (80.0%) | < 0.001 | |
| Antiplateletc | 895 (59.8%) | 43 (66.2%) | 0.37 | |
| Amiodarone | 149 (9.9%) | 13 (20.0%) | 0.019 | |
| Patients possessing ≥ 1 minor allele | ||||
| CYP2C9*2 | 200 (16.4%) | 8 (16.7%) | 0.75 | |
| CYP2C9*3 | 98 (8.0%) | 5 (10.4%) | 0.73 | |
| CYP2C9 *5, *6, *11 | 18 (1.5%) | 1 (2.1%) | 0.73 | |
| VKORC1 | 523 (41.2%) | 22 (44.0%) | 0.74 | |
| CYP4F2 | 439 (36.8%) | 15 (32.6%) | 0.56 | |
| rs12777823 | 429 (36.0%) | 11 (23.9%) | 0.09 | |
Data are mean ± SD values or no. (%) of patients.
eGFR = estimated glomerular filtration rate.
a
Patients may have had more than one indication for anticoagulation.
b
Statins included any of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
c
Antiplatelet agents included aspirin, clopidogrel, and dipyridamole as monotherapy or dual therapy.